Feed GRTX
Summary
39 / 100 · Bulios Score
Valuation 30Growth -Profitability -Quality 21Debt 100Stability 4
What speaks for it
- It has no debt and holds $5.50M in cash.
What to watch
- It passes only 2 of the 9 points of the Piotroski financial health test.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveP/E today 23.9
Biotechnology industry median
Today you pay 23.9 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
20212022202320242025
Diluted EPS (USD)
20212022202320242025
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $5.50M
Debt $0.00
Free cash flow over 12 months -$1.63M
It has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 3
- Sell 0
No analyst has published a price target.
67% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.